113P - Enumeration and molecular characterization of circulating tumor cells in lung cancer patients using the GILUPI CellCollector

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Non-small-cell lung cancer
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Claudia Chudak
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors C. Chudak1, J. Herrmann2, T. Lesser2
  • 1Clinical Research, GILUPI GmbH, 14473 - Potsdam/DE
  • 2Clinic Of Thoracic And Vascular Surgery, SRH Waldklinikum Gera, Gera/DE

Abstract

Background

Analysis of tumor biopsy material represents only assessable tumor and represents the state at the time of diagnosis. This approach neglects tumoral heterogeneity changes occurring during disease progression. However, during systemic therapies tumors undergo molecular changes and usually develop resistance mechanisms. Reevaluation of tumors after therapy, at disease progression and before new treatment initiation would be informative for the selection of appropriate next steps. However, re-biopsies are not often feasible and can cause morbidity. Liquid biopsy, i.e. isolating and analyzing circulating tumor cells (CTCs), can be an additional source of diagnosis, prognosis, evaluation of treatment efficacy, and molecular tumor evolution and metastatic sites. The GILUPI CellCollector®, an intravascularly in-dwelling device, screens blood for CTCs directly in the vein of the cancer patient. The device has specific monoclonal antibodies attached to pull down epithelial derived CTCs. Here, we conducted a study using this effective device, to monitor CTC counts before as well as on different time points after surgery in non-small cell lung cancer (NSCLC) patients.

Methods

In total, 18 lung cancer patients (with different stages) were screened for CTCs at different time points: preoperative, 30 minutes after resection, 1 week postoperative as well as in 3-monthly intervals up to 2 years. In addition, 1 patient with a benign lung disease were included in this study.

Results

Applying the GILUPI CellCollector®, CTCs were isolated independent from the tumor stages and tumor size. Moreover a difference between CTC occurrence before and after surgery was seen and we were able to detect a correlation between CTC enumeration and clinical lack of recurrence.

Conclusions

The GILUPI CellCollector® overcomes blood volume limitations of other diagnostic approaches and thereby increases the diagnostic sensitivity of CTC analysis. It allows enumeration and molecular characterization of CTCs which might help to monitor therapy efficacy and improve treatment strategies.

Clinical trial identification

Legal entity responsible for the study

Thomas Lesser

Funding

GILUPI GmbH

Disclosure

All authors have declared no conflicts of interest.